(PRWEB) December 05, 2013
The Corporate Whistleblower Center says,“There are FDA rules designed to keep patients safe and informed about the potential dangers of prescription drugs. When pharmaceutical companies deliberately ignore these rules for their own gain, they put the health of their patients at risk. They also present opportunities for whistleblowers to step forward, do the right thing, and be rewarded handsomely as a result, as we would like to explain if a potential whistleblower calls us at 866-714-6466.”
According to a recent release from the Department of Justice, Johnson & Johnson agreed to pay $2.2 billion to settle allegations it promoted and encouraged the use of the drug Risperdal, an anti-psychotic approved only for schizophrenia, to elderly patients with dementia and children with mental disabilities, allegedly despite knowing it was not safe for these disorders. Allegedly many of these prescriptions were filled using Medicare funds. The lawsuit also alleged that that J&J and subsidiary Janssen paid illegal speaking fees to doctors, telling them they would only be paid if they increased sales of Risperdal. They also allegedly paid kickbacks to Omnicare, which dispenses prescriptions to nursing homes, for recommending their drugs.
The whistleblowers in this case, who came from a variety of states, received staggering awards of $112 million, $27.7 million, and $28 million.
“As you can see from this case, whistleblower rewards can be astronomical,” says the Corporate Whistleblower Center. “If you have proof a pharmaceutical company is involved in off-labeling and/or physician and pharmacy kickbacks, and you have well documented proof, contact us at 866-714-6466, so we can carefully explain federal whistleblower programs to you." http://CorporateWhistleblowerCenter.Com
Simple rules for a whistleblower from the Corporate Whistleblower Center:
Any type of insider or employee who possesses significant proof of their employer or a government contractor defrauding the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466 or via their web site at http://CorporateWhistleBlowerCenter.Com
For attribution purposes please refer to the November 2013 press release regarding this matter. http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html
Case number: U.S. ex rel. Starr v. Jansseen Pharmaceutical Products, L.P., No. 04-cv-1529, E.D. Pa.